# VYXEOS

NDC: 68727-745
Generic name: (daunorubicin and cytarabine) liposome
Labeler / Manufacturer: Jazz Pharmaceuticals, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
Routes: INTRAVENOUS
Marketing started: 20170803

FDA application: NDA209401

## Active ingredients

- CYTARABINE: 100 mg/20mL
- DAUNORUBICIN: 44 mg/20mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"68727-745"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=68727-745
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7ea701ce-e7d3-4349-a9c2-642a501d45c8